NEW YORK, July 16, 2026, 10:05 a.m. EDT
- U.S. cash markets were open. AtaiBeckley traded near $7.04, up about 31%.
- Lilly’s $6.75 cash bid leaves roughly $0.29 of preliminary implied CVR value.
- VLS-01 accounts for 80% of the deal’s $2.50 contingent payment.
AtaiBeckley Inc. (NASDAQ: ATAI) jumped about 31% to $7.04 on Thursday. Eli Lilly and Co. (NYSE: LLY) agreed to buy the company for up to $3.8 billion.
The stock sat only 29 cents above Lilly’s $6.75 cash offer. That gap is the clearest investor signal. A preliminary, undiscounted calculation values the $2.50 CVR at roughly 11% of face value.
Most of that potential upside rests on one program. VLS-01 accounts for $2, or 80%, of the contingent payment. It remains in Phase 2b development. BPL-003, the lead asset, accounts for only 50 cents.
Lilly will pay $6.75 per share at closing. That is 26% above Wednesday’s $5.36 close and 40% above the 30-day average. The companies expect a third-quarter close.
| Deal component | Per share | Share of CVR | Deadline |
|---|---|---|---|
| Cash at closing | $6.75 | — | Expected third quarter |
| VLS-01 Phase 3 initiation | $1.00 | 40% | Before fourth closing anniversary |
| BPL-003 approval and DEA rescheduling | $0.50 | 20% | Before fifth anniversary |
| VLS-01 approval and DEA rescheduling | $1.00 | 40% | Before seventh anniversary |
| Maximum consideration | $9.25 | 100% | All milestones achieved |
| Preliminary market-implied CVR | $0.29 | About 11% | Based on $7.04 stock price |
The market-implied calculation ignores time value and closing risk. It is not a probability estimate.
That split shifts the speculative value toward VLS-01. The drug is a DMT buccal film in an ongoing Phase 2b study. Its first $1 milestone requires a Phase 3 start within four years.
BPL-003 is further ahead. It has initiated Phase 3 activities and holds FDA breakthrough status. Yet its approval and DEA milestone pays only 50 cents.
The structure suggests Lilly’s cash bid captures most current value for BPL-003. Investors paying above $6.75 are mainly buying VLS-01 optionality.
Lilly Neuroscience President Carole Ho said patients “desperately need a therapy that works.” AtaiBeckley Chief Executive Srinivas Rao said Lilly’s reach should accelerate development. AtaiBeckley Inc.
BMO analyst Evan Seigerman said the target offers “differentiated exposure in psychiatry.” He also pointed to Lilly’s push beyond cardiometabolic drugs. Reuters
The sector read-through was mixed after the opening bell. GH Research PLC (NASDAQ: GHRS) gained about 7%, while Compass Pathways PLC (NASDAQ: CMPS) fell about 3%. That suggests investors viewed the deal as asset-specific.
Risks: AtaiBeckley shareholders and regulators must approve the merger. The CVR can expire worthless if trials, approvals or DEA rescheduling miss deadlines.
For now, $6.75 remains the market’s anchor. The extra 29 cents measures current confidence in the milestones.
